Amgen's trebananib down, not out in ovarian cancer
This article was originally published in Scrip
Trebananib did not significantly improve overall survival for women with recurrent ovarian cancer, a secondary endpoint of the TRINOVA-1 trial, but Amgen has two more Phase III opportunities to show a meaningful improvement for patients with the difficult cancer.
You may also be interested in...
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.